Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
07:45am, Monday, 02'nd Sep 2024
Recent results from Bristol Myers Squibb support an improving outlook. The company is benefiting from strong demand for its new medications.
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
06:53am, Sunday, 01'st Sep 2024
An investment in these two stocks could pay off handsomely over the next five to 10 years. Bristol Myers is an established healthcare business with a portfolio of blockbuster drugs.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients.
Bristol Myers Squibb (BMY) Advances But Underperforms Market: Key Facts
06:45pm, Friday, 30'th Aug 2024
Bristol Myers Squibb (BMY) closed at $49.95 in the latest trading session, marking a +0.46% move from the prior day.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
10:01am, Thursday, 29'th Aug 2024
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Magnificent 7 Dividend Stocks Every Passive Income Investor Should Own
08:13am, Thursday, 29'th Aug 2024
24/7 Wall St. Insights Dividend stocks are starting to outperform in the second half of 2024.
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
07:01pm, Wednesday, 28'th Aug 2024
Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
11:16am, Wednesday, 28'th Aug 2024
Wednesday, Neurocrine Biosciences, Inc. NBIX topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
3 High-Yield Dividend Stocks With Payout Ratios Below 75%
07:00am, Wednesday, 28'th Aug 2024
Dividend stocks with less-than 75% payout ratios tend to outperform long term. The high-yield dividend payers AT&T, Bristol Myers Squibb, and Chevron stand out on this crucial measure.
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
05:37am, Wednesday, 28'th Aug 2024
The benchmark S&P 500 index is way up over the past year, but some of its dividend-paying components haven't participated in the gains. Bristol Myers Squibb's dividend offers a high yield that could r
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
03:28pm, Thursday, 22'nd Aug 2024
Bristol-Myers Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings.
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
11:50am, Thursday, 22'nd Aug 2024
Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
02:05pm, Tuesday, 20'th Aug 2024
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
04:39am, Tuesday, 20'th Aug 2024
Bristol Myers Squibb doesn't sell anti-obesity drugs, but it can keep raising its dividend payout without them. Shares of Dow Inc. offer a yield above 5%, and there's a good chance the company can beg
Where Will Bristol Myers Squibb Be in 5 Years?
09:24am, Sunday, 18'th Aug 2024
Bristol Myers Squibb will face major losses of patent exclusivity by 2029. BMS has launched a number of brand-new approvals to replace older products.
